Safety of Orexin Receptor Antagonist on Cardiac and Respiratory Function in Patients who Underwent Off-pump Coronary Artery Bypass Grafting

Objective: We assessed the safety of Suvorexant, an orexin receptor antagonist, on cardiac and respiratory function in patients who underwent off-pump coronary artery bypass grafting (OPCAB) retrospectively. Materials and methods: We investigated 66 patients including 16 women (mean age 71.6±8.1 years) who underwent OPCAB alone at our hospital. Patients were categorized as those received orexin receptor antagonist after OPCAB (S-group, n=35) or without orexin receptor antagonist (N-group, n=31), and the following data were analyzed between both groups. Results: The incidence of postoperative delirium was significantly lesser in the S-group than in the N-group (N vs. S =32.3 % vs. 8.6 %, p=0.004). Intensive care unit stay was also significantly shorter in the S-group compared with the N-group (N vs. S=4.6±1.1 vs. 4.1±0.8 days, p=0.040). No significant intergroup difference was observed in arterial blood gas measurement (mean the potential of hydrogen, partial pressure of oxygen, the partial pressure of carbon dioxide, base excess, and respiratory rate) and circulation statement (systolic arterial blood pressure, pulmonary artery wedge pressure, heart rate, cardiac index, and mixed venous oxygen saturation) before and after the administration of Suvorexant. Conclusion: Orexin receptor antagonists didn’t worsen the cardiac function and the respiratory function in patients who underwent OPCAB.